Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Limitless X Holdings Inc.LIMX · Entity 7910 | Director | January 13, 2025 | January 15, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Limitless X Holdings Inc.
Report date January 13, 2025 · Filed January 15, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | Direct | 421,000 |
Reported balance
After 2025-01-13 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-01-13 · Grant · Acquired 315,000 · Balance 421,000 F1: Reflects the issuance of shares of the issuer's common stock in consideration for accrued compensation owed to the reporting person in connection with her services rendered as a director of the issuer from May 20, 2022 through December 31, 2024. F2: On December 19, 2022, the issuer effected a 1-for-30 reverse stock split. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the issuance of shares of the issuer's common stock in consideration for accrued compensation owed to the reporting person in connection with her services rendered as a director of the issuer from May 20, 2022 through December 31, 2024.
F2: On December 19, 2022, the issuer effected a 1-for-30 reverse stock split.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 13, 2025 Filed Jan 15, 2025 15:02 UTC | Limitless X Holdings Inc. LIMX · Entity 7910 | GrantCommon Stock, par value $0.001 per share | 315,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-25-002296 · ownership.xml · nonDerivative · entry 1 Saccomanno Amanda Rose · CIK 0001939164 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 421,000 F1 · shares: Reflects the issuance of shares of the issuer's common stock in consideration for accrued compensation owed to the reporting person in connection with her services rendered as a director of the issuer from May 20, 2022 through December 31, 2024. F2 · balance_after: On December 19, 2022, the issuer effected a 1-for-30 reverse stock split. Read SEC document |
| August 12, 2022 Filed Oct 31, 2022 23:27 UTC | Limitless X Holdings Inc. VYBE · Entity 7910 | OtherCommon Stock, par value $0.001 per share | 270,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-22-067819 · ownership.xml · nonDerivative · entry 1 Saccomanno Amanda Rose · CIK 0001939164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,180,000 F1 · kind: Pursuant to a Share Exchange Agreement dated May 11, 2022 (the "Agreement"), by and between Limitless X Holdings Inc. and Bio Lab Naturals Inc., the reporting person was to be issued 270,000 additional shares of common stock after the closing of the Agreement. The reporting person exercised their right to receive those additional shares on August 12, 2022. F1 · price: Pursuant to a Share Exchange Agreement dated May 11, 2022 (the "Agreement"), by and between Limitless X Holdings Inc. and Bio Lab Naturals Inc., the reporting person was to be issued 270,000 additional shares of common stock after the closing of the Agreement. The reporting person exercised their right to receive those additional shares on August 12, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.